Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients?

BACKGROUND: The prognosis of patients with NSCLC harboring oncogenic driver gene alterations, such as EGFR gene mutations or ALK fusion, has improved dramatically with the advent of corresponding molecularly targeted drugs. As patients were followed up for about five years in most clinical trials, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimamura, Shoko Sonobe, Shukuya, Takehito, Asao, Tetsuhiko, Hayakawa, Daisuke, Kurokawa, Kana, Xu, Shiting, Miura, Keita, Mitsuishi, Yoichiro, Tajima, Ken, Shibayama, Rina, Shimada, Naoko, Takahashi, Fumiyuki, Takahashi, Kazuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953392/
https://www.ncbi.nlm.nih.gov/pubmed/35337281
http://dx.doi.org/10.1186/s12885-022-09421-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953392/
https://www.ncbi.nlm.nih.gov/pubmed/35337281
http://dx.doi.org/10.1186/s12885-022-09421-7

Ejemplares similares